Home > Insider Trading > Filing (0001209191-22-035225)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Biosciences Inc.	PCRX	Pharmaceutical Preparations (2834)	510619477

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1752004	Dennis Mcloughlin	C/O Pacira Biosciences, Inc. 5401 West Kennedy Boulevard, Suite 890 Tampa FL 33609	Chief Customer Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-06-06	2,140	$61.37	31,820	No	4	S	Direct
Common Stock	Acquisiton	2022-06-08	7,950	$0.00	39,770	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-06-08	19,900	$0.00	19,900	$59.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
19,900		2032-06-08	No	4	A	Direct

Footnotes

Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
Includes 258 and 161 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021 and December 2021, respectively.
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.